Careers  |  Sign In  |  Register  |   Twitter

Peanut Immunotherapy May Treat Allergy

New research in The Journal of Allergy and Clinical Immunology investigates “the safety, efficacy, and immunologic effects of peanut sublingual immunotherapy (SLIT).” Following 44 weeks of SLIT, the study found 70% of subjects receiving peanut SLIT were responders compared with 15% of subjects receiving placebo (P < .001). “In peanut SLIT responders, median SCD (successfully consumed dose) increased from 3.5 to 496 mg. After 68 weeks of SLIT, median SCD significantly increased to 996 mg (compared with Week 44, P = .05) … Of 10,855 peanut doses through the Week 44 OFCs, 63.1% were symptom free; excluding oral-pharyngeal symptoms, 95.2% were symptom free.

Read it in The Journal of Allergy and Clinical Immunology.